Smoking cessation: the decision in every visit

A woman in her fifties returns to the clinic to show her blood glucose result. The appointment is running late, the waiting room is full, and the question about cigarettes comes at the end, almost like a form item: "Still smoking?". She says yes, that she has already tried to quit three times and that "there is no way". The person seeing her writes "smoker, not interested in quitting" and moves on to the prescription. In less than a minute, one of the highest-impact treatment decisions of the visit was made without anyone noticing it was a decision. This text uses smoking cessation as a scenario for clinical reasoning: why cigarettes deserve the same care as any other active problem, how to turn the question into action, how to think about the choice between treatment options and how to read relapse as clinical data, not as failure. The scene and the examples throughout the text are fictional and were written for teaching.

NEXO is a daily medical diagnosis game: one clinical case a day, up to six progressive clues, and ICD-10 proximity feedback across five levels.

The text avoids being a prescribing or dosing guide. Guidelines such as the World Health Organization's and NICE's guide treatment, and each service has its own protocols. Here the focus is on the way of thinking: what information to collect, which biases get in the way and how to decide together with the person. If you play the case of the day on NEXO, you already know the move: a clue that seems small, such as cigarettes mentioned in passing, can change the weight of several hypotheses at the same time.

Key points

• Asking about tobacco and offering help is a treatment decision, and it deserves the same reasoning as any other problem on the list.
• Systematic reviews show that brief physician counseling increases quit attempts, and that offering concrete help works better than just recommending cessation.
• The choice between nicotine replacement, varenicline, cytisine and bupropion depends on evidence, preference, comorbidities and the person's previous experience.
• Relapse is part of the natural course of nicotine dependence and brings useful information for the next attempt.
• Biases such as therapeutic nihilism and diagnostic overshadowing make smoking disappear from the visit.

Why cigarettes are a clinical decision, not a form item

The visit record usually treats smoking as history: smoker, former smoker, never smoked. The record is useful, but it freezes information that changes at every visit. The person who smoked twenty cigarettes a day last year may have cut down, gone back to smoking, switched products or be thinking about quitting right now. Treating tobacco as an active problem, with its own action in the problem list, changes the question from "do you smoke?" to "what are we going to do about cigarettes today?".

The World Health Organization describes tobacco as one of the greatest public health threats ever faced and notes that nicotine dependence is a treatable condition (WHO, tobacco fact sheet). The WHO clinical guideline for treating tobacco cessation, published in 2024, recommends that health professionals routinely offer brief counseling and treatment to people who use tobacco (WHO, cessation treatment guideline). NICE follows the same line in guideline NG209, which covers prevention and treatment of smoking in different care settings (NICE NG209).

From a reasoning standpoint, cigarettes are a clue that crosses chapters. They raise the pre-test probability of cardiovascular disease, chronic obstructive pulmonary disease, several cancers, healing complications and problems in pregnancy. At the same time, they are a possible treatment: quitting smoking is an intervention with an effect on many of these conditions. When you record smoking and move on, you lose both things: the diagnostic clue and the treatment decision.

Tobacco as a clue in almost every case

In teaching clinical cases, smoking often appears as a detail in the social history. In chest pain, it shifts the probability toward coronary syndrome. In chronic cough, it opens the door to obstructive pulmonary disease and to neoplasm. In an ulcer that does not heal, it suggests peripheral arterial disease. The post about pretest probability shows how one piece of history information changes the reading of a test. Tobacco does this often, so it is worth asking in full: for how long, how much, which product, and whether the person has already tried to quit.

The short visit and the decision that goes missing

Lack of time is the most cited reason for skipping the conversation about smoking. The problem is that the decision not to talk is also a decision, just one made without thinking. If you have read the post about clinical decision-making, you will recognize the pattern: practices that nobody chooses explicitly end up being chosen by habit. The solution involves having a short script that fits into a few minutes and always ends with a concrete offer.

Brief counseling that fits into any visit

The evidence on brief counseling is old and consistent. The Cochrane review on physician advice for smoking cessation gathered trials in different settings and concluded that simple advice from the physician increases the chance that the person quits, with a slightly larger effect when the intervention is more intensive (Stead et al., 2013). This means that even a short conversation has value, as long as it happens.

A systematic review with meta-analysis published in Addiction compared two forms of brief intervention: advising quitting for health reasons and offering help to quit. Offering help led to more quit attempts than advice alone (Aveyard et al., 2012). The difference seems small, but it changes the logic of the conversation: instead of convincing the person that smoking is harmful, something they usually already know, you offer a path.

A short script in three moves

Several brief counseling models use the same structure. You can adapt the language, as long as you keep the three steps:

1. Ask and record. "Do you smoke or use any nicotine product? How much, and for how long?" Also record previous attempts and what happened with them.
2. Advise clearly and personally. Link the advice to the reason for the visit: "Quitting smoking is one of the things that helps your blood pressure and your heart the most."
3. Offer concrete help. "There are treatments that increase your chances. Would you like us to choose one today?" If the person accepts, agree on the start and the follow-up. If they refuse, record it and bring it up again at the next visit.

The third step is the one most often lost. It turns the conversation into a therapeutic decision and creates a checkpoint for the next visit.

When the person says they do not want to quit now

Refusal is information, not a full stop. The Cochrane review on motivational interviewing for smoking cessation found a possible benefit compared with brief advice or usual care, with certainty of evidence rated low (Lindson et al., 2019). What this approach offers to reasoning is a way to explore ambivalence without confrontation: what the person likes about smoking, what bothers them, what would change if they quit. The post about empathy and clinical reasoning in the visit shows how listening improves the quality of the information that enters your reasoning.

How to choose among treatment options

Once the person accepts help, the question changes to which treatment to offer. Here the reasoning resembles any therapeutic choice: you compare efficacy, safety, preference, previous experience and access. The text avoids doses and regimens, which follow the package insert, the local guideline and the individual assessment.

The Cochrane review on nicotine replacement therapy showed that all marketed forms, such as patch, gum, lozenge, spray and inhaler, increase the chance of cessation compared with control (Hartmann-Boyce et al., 2018). The review on partial nicotinic receptor agonists, which includes varenicline and cytisine, found high-certainty evidence that varenicline increases cessation, with a greater effect than bupropion and than nicotine replacement as monotherapy (Livingstone-Banks et al., 2023).

Two network analyses help compare the options with each other. The overview with network meta-analysis published by Cochrane in 2013 indicated that combined nicotine replacement, for example a patch with a fast-acting form, and varenicline perform similarly and better than a single form of replacement (Cahill et al., 2013). The component analysis published in 2023, which also included electronic cigarettes with nicotine, placed varenicline, cytisine and combined replacement among the most effective interventions (Lindson et al., 2023).

Neuropsychiatric safety and the fear that blocks prescribing

For years, concern about neuropsychiatric effects led many professionals to avoid varenicline and bupropion in people with a psychiatric history. The EAGLES trial, published in Lancet, compared varenicline, bupropion, nicotine patch and placebo in smokers with and without psychiatric disorders and found no significant increase in serious neuropsychiatric events with the active medications compared with placebo (Anthenelli et al., 2016). This changes the reasoning: a psychiatric history calls for close follow-up, and it also calls for the person to have access to the most effective treatment.

Where guidelines and nicotine products come in

WHO and NICE guidelines differ on some points, especially about electronic cigarettes with nicotine. The position of each service follows the local guideline and each country's regulation. For the reasoning, the essential step is to ask about all nicotine products, because they change the assessment of dependence and the choice of treatment.

Table: treatment options and what to weigh in the choice

The table summarizes the options cited in the reviews and guidelines in this text. It serves as a map for the reasoning, and prescribing follows the package insert, the local guideline and the individual assessment.

Option	What the evidence shows	What to weigh in the choice
Brief advice	Increases attempts and cessation, with more effect when it includes an offer of help	Fits into any consultation; it needs to end with a concrete proposal
More intensive behavioral support	Adds effect to pharmacological treatment	Local availability, preference and the person's time
Nicotine replacement as monotherapy	All forms increase cessation compared with control	Preference for the form; previous experience with the product
Combined nicotine replacement	Performance similar to varenicline in network meta-analyses	Combines continuous release with a rescue dose for craving
Varenicline	High-certainty evidence of benefit; superior to bupropion and to replacement alone	Nausea and vivid dreams; kidney function; follow-up in psychiatric history
Cytisine	Benefit in recent reviews; it appears among the most effective options	Availability and regulation in each country
Bupropion	Increases cessation, with a smaller effect than varenicline	Contraindications such as a history of seizure; interactions

Relapse as clinical data

Most attempts to quit without help end in relapse, and many relapses happen in the first days. A classic study in Addiction analyzed the relapse curve in smokers who tried to quit without treatment and showed that long-term abstinence is low in this group, with most relapses concentrated at the start (Hughes, Keely and Naud, 2004). For clinical reasoning, this finding has two consequences. The first is that the previous attempt without help counts little as proof that "there is no way". The second is that follow-up in the first weeks is the moment of greatest value.

When someone says they have already tried to quit three times, the useful question is what happened in each attempt. Did they use any treatment? For how long? In what situation did they start smoking again? Did they have intense withdrawal symptoms, weight gain, worsening mood or sleep? Each answer guides the next choice: switching medication, combining forms of replacement, strengthening behavioral support or planning the strategy for high-risk situations.

What to ask after a relapse

Five questions help turn a relapse into information. How long did you stay smoke-free, and what was happening when you started again? What treatment did you use, at what dose and for how long? Which symptoms bothered you most: craving, irritability, sleep, appetite? What situations usually come before the cigarette: coffee, alcohol, stress, other people smoking? What worked, even if only for a short time?

From failure to adjusting the approach

Calling a relapse a failure puts the entire responsibility on the person and ends the reasoning. Reading a relapse as data opens the next treatment hypothesis. The logic is the same as in the post about diagnostic uncertainty: you decide with the information available, observe the result and adjust. Nicotine dependence is a chronic condition with relapses, and continuous care is the model that fits it best.

The biases that make smoking disappear from the consultation

Smoking is a good example of how cognitive biases affect conduct, and not only diagnoses. Pat Croskerry described several of these errors and proposed strategies to reduce them (Croskerry, 2003). In smoking cessation, four appear often.

Therapeutic nihilism

It is the belief that the intervention is not worth the effort because "nobody really quits". The evidence from the reviews cited points the other way: brief counseling and pharmacological treatment increase cessation. Therapeutic nihilism usually comes from remembering the people who started smoking again, and not from a real count of outcomes. The post about examples of heuristics in clinical reasoning describes the availability heuristic, which helps explain this effect.

Obfuscation by the main problem

The person arrives with uncontrolled diabetes, low back pain or an acute complaint, and the cigarette is left for later. The problem is that "later" rarely comes. The post about the patient with many complaints proposes organizing the problem list by priority and by impact. Because of its impact on almost every other condition, tobacco deserves its own line on that list.

The "not motivated" label

A single negative answer becomes a permanent note in the medical record. In the following consultations, nobody asks again. Motivation changes over time, with health events and with the way the question is asked. The useful record includes the date and the answer: "On October 23, preferred to postpone; revisit at the next follow-up".

Omission bias

Prescribing a treatment and seeing an adverse effect seems worse than not prescribing and seeing the person keep smoking. This imbalance makes the professional avoid the decision. The EAGLES trial and the reviews cited offer a basis for weighing risks and benefits more fairly.

How to talk about cigarettes without blame and without a lecture

Language matters in smoking as much as in other forms of substance use. A randomized study with mental health professionals showed that describing the same person as a "substance abuser" instead of a "person with a substance use disorder" increased the tendency to assign blame and to support punitive measures (Kelly and Westerhoff, 2010). With cigarettes, blame usually appears in phrases like "haven't you managed to kick that habit yet?". This tone makes the person hide information and reduces the chance that they accept help.

A few simple swaps improve the conversation:

• Replace "habit" with "nicotine dependence", which describes a treatable condition.
• Replace "you need to quit" with "quitting is one of the best things for your health, and I can help".
• Ask about the person's experience before proposing treatment.
• Value previous attempts as learning, not as failure.
• Record in the medical record the decision made and the next step, in neutral language.

The conversation in special situations

In pregnancy, during hospitalization, before surgery and in people with mental disorders, the cigarette carries extra weight and the conversation needs more care. Each of these situations has specific recommendations in the cited guidelines. The reasoning point is the same: the opportunity for intervention exists at all these moments, and the decision to offer treatment follows the individual assessment and the rules of the service.

How to train with cases and with NEXO

NEXO offers a fictional clinical case per day, with a real clinical presentation and up to six progressive clues. You propose a diagnosis by searching for the ICD-10 code and receive a proximity feedback in five levels, which shows whether the guess landed on the exact code, the same category, the same group, the same chapter or another chapter. Tobacco appears in cases from several chapters, and noticing when it is the clue that changes everything is a good reasoning exercise.

Three exercises to train with cases

Reasoning about smoking cessation is trained like any therapeutic decision: with cases, with feedback and with reflection on what you failed to do. The post on learning based on clinical cases explains why this form of study fixes decisions better.

Look for the cigarette in the history. When reading a case, mark every time tobacco appears and ask which hypotheses it makes more likely.

Close the case with a course of action. After reaching the diagnosis, write down what the decision about cigarettes would be at that visit, even if the case is about another problem.

Rewrite the relapse. Take a fictional record such as "patient did not adhere to treatment" and rewrite it with useful information: what was used, for how long and what happened.

These exercises match the idea of calibration described in the post on calibration of confidence in diagnosis: comparing what you decided with what the evidence suggests.

The limits of use of the game are described on the NEXO economy page. If you research the teaching of clinical reasoning, the page for researchers explains how to get in touch. Professionals who write or review cases find information in curation and in creators, and institutions can learn about the proposal on the partnerships page.

Frequently asked questions

Is it worth talking about cigarettes in a visit of a few minutes?

It is. The Cochrane review on medical advice shows that even brief interventions increase cessation. The central point is to end the conversation with a concrete offer of help.

Which treatment is the most effective for quitting smoking?

The cited reviews place varenicline, cytisine and combination nicotine replacement among the most effective options. The final choice depends on the person, the comorbidities, previous experience and the local guideline.

Can people with mental disorders receive varenicline or bupropion?

The EAGLES trial included smokers with and without psychiatric disorders and found no significant increase in serious neuropsychiatric events with the medications compared with placebo. The decision follows the individual assessment, with careful follow-up.

Does a relapse mean the treatment failed?

Relapse is common in nicotine dependence and brings useful information. Understanding what happened helps to choose the next strategy.

Does this text serve as a prescription protocol?

This text deals with clinical reasoning and therapeutic decision. Doses, regimens and contraindications follow the package insert, the guidelines and the protocols of your service, under supervision.

How does this topic appear in exams?

Exams usually test brief counseling, the choice among pharmacological options, the main contraindications and the approach to the ambivalent person. Training with cases helps to connect these points.

Final checklist

• I asked about all nicotine products, not only about cigarettes.
• I linked the advice to the reason for the visit, in clear language and without blame.
• I offered concrete help and recorded the response with a date.
• I compared the treatment options based on evidence, preference and comorbidities.
• I asked what happened in previous attempts.
• I set the follow-up, with special attention to the first weeks.

Want to practice reasoning with progressive clues? Play the case of the day.

References

1. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016. PMID 27116918.
2. Aveyard P, Begh R, Parsons A, et al. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction. 2012. PMID 22175545.
3. Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013. PMID 23728690.
4. Croskerry P. The importance of cognitive errors in diagnosis and strategies to minimize them. Acad Med. 2003. PMID 12915363.
5. Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018. PMID 29852054.
6. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004. PMID 14678060.
7. Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010. PMID 20005692.
8. Lindson N, Thompson TP, Ferrey A, et al. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2019. PMID 31425622.
9. Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023. PMID 37696529.
10. Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023. PMID 37142273.
11. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209). 2021. NICE NG209.
12. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013. PMID 23728631.
13. World Health Organization. WHO clinical treatment guideline for tobacco cessation in adults. 2024. OMS.
14. World Health Organization. Tobacco: fact sheet. OMS.